This antibody was developed as part of a collaboration between Abcam and Professor Charles Glabe, UC Irvine.
mOC64 immunoreactivity maps to residues 3-6 (EFRH) of Aß. It does not recognize pyproglytaminylated Aß at position 3 (Aß3(pE)–42) (Nussbaum et al. 2012;Hatami et al. 2014).
For further information on the immunogen, please refer to Hatami et al. 2014 and Kayed et al. 2007.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
General notes
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.